NYSE:JNJ
Johnson & Johnson (JNJ)
250.92
+2.10 (0.84%)
as of Jul 21, 2026, 8:03:09 pm Market Open.
697 watching
Financials 
Technical Analysis 0
Investor Insights
Jul 21, 2026, 12:00 amThis summary was created by AI, based on 10 opinions in the last 12 months.
Johnson & Johnson (JNJ) has shown strong performance in the pharmaceutical sector, particularly after spinning off its orthopedics division. Despite challenges in the cardio business and ongoing talcum-cancer lawsuits, expert opinions are largely optimistic about the company's future prospects. The current focus on high-margin areas like medical devices and pharmaceuticals, combined with a strong drug pipeline, positions JNJ for growth. Although the stock may experience fluctuations around earnings reports, it is generally viewed as a buy during dips. Overall, experts suggest that JNJ remains a sound investment, particularly for those interested in dividend growth and potential additional upside.
Consensus
Buy
Valuation
Fair Value
Similar
PG
BUY
Large-cap fully integrated global pharmaceutical. Earnings beat expectations. Competition from generics but their pipeline going forward looks extremely robust.
Brett HrybOwned
biotechnologypharmaceutical
BUY
Consumer staples, pharmaceuticals, utilities and telecoms have been have been enormous under performers during this rally. Rock solid. Pretty decent dividend.
Gavin GrahamOwned
biotechnologypharmaceutical
TOP PICK
Globally diversified operations including pharmaceutical, medical devices and consumer products. Over half their business is outside of the US. Trading around 8X EBITDA. Virtually no net debt. Have a real diverse group of pharmaceuticals coming on in the next 4 years. Good defensive holding.
Ara NalbandianOwned
biotechnologypharmaceutical
TOP PICK
Not a purely pharmaceutical company. Also healthcare and medical devices. Great dividend and great balance sheet. Warner-Lambert was a great acquisition.
Paul Harris, CFAOwned
biotechnologypharmaceutical
TOP PICK
High quality large-cap and is undervalued. Trading at the lowest multiple in its 20-year history. You're getting it at about 11X earnings.
Charles BobrinskoyOwned
biotechnologypharmaceutical
BUY
Very well positioned. A defensive name so has held up very well. Consistent in their earnings streams so you don't have to be concerned about dividends. Starting to expand into growing areas i.e. medical devices as well as having a fairly large international expansion plan.
Michael YoshikamiOwned
biotechnologypharmaceutical
TOP PICK
Diversified businesses including consumer products, medical devices and pharmaceuticals. Great balance sheet. Created great shareholder value. 3.5% dividend.
Paul Harris, CFAOwned
biotechnologypharmaceutical
BUY
Have a very strong consumer product business and thinks they could weather pharmacy pipeline issues. 11 PE.
David AbellaOwned
biotechnologypharmaceutical
TOP PICK
Very strong balance sheet. Have 3 really great businesses including consumers, medical devices and pharmaceuticals. Made a very good acquisition from Pfizer (PFE-N) of their consumer products. Nice dividend of 4.5%.
Paul Harris, CFAOwned
biotechnologypharmaceutical
HOLD
Have medical devices, consumer healthcare and pharmaceuticals. Pharma has had a lot of patent expiries in the last few years but it will start to grow in 2010. Suspects they will increase the dividend in April.
Charles LannonOwned
biotechnologypharmaceutical
BUY
One of the most respected companies globally. Should be able to produce good growth. Bought Pfizer's (PFE-N) consumer business. Trading at the lowest multiple that they have traded at in at least 20 years.
Charles BobrinskoyOwned
biotechnologypharmaceutical
TOP PICK
Great balance sheet. Great assets from consumers to medical devices to pharmaceuticals. In this environment, they can really grow their business through acquisition in the healthcare area. Almost 4.5% yield. Doesn't think it will fall a lot.
Paul Harris, CFAOwned
biotechnologypharmaceutical
HOLD
More defensive than not. Has a great set of products. Longer-term it could regain its status as a defensive stock.
David AbellaOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
